Back

Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)

Yorsaeng, R.; Vichaiwattana, P.; Klinfueng, S.; Wongsrisang, L.; Sudhinaraset, N.; Vongpunsawad, S.; Poovorawan, Y.

2021-09-03 infectious diseases
10.1101/2021.09.01.21262955
Show abstract

Limited COVID-19 vaccines in many countries have delayed mass-immunization. Although individuals fully vaccinated with Vaxzevria (AstraZeneca) have higher antibody levels than those with CoronaVac (Sinovac), heterologous prime-boost with CoronaVac-Vaxzevria yielded comparable antibody levels to two-dose Vaxzevria. Combination use of different available vaccines may be warranted in Thailand, which faces limited vaccine choice and supply.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Vaccines
○ based on 131 papers
Top 0.1%
17.7%
2
Vaccine
○ based on 140 papers
Top 0.4%
16.0%
3
Human Vaccines & Immunotherapeutics
○ based on 20 papers
Top 0.1%
8.6%
4
PLOS ONE
● based on 1737 papers
Top 65%
5.5%
5
The Lancet Infectious Diseases
○ based on 57 papers
Top 0.9%
5.3%
50% of probability mass above
6
International Journal of Infectious Diseases
○ based on 115 papers
Top 3%
3.1%
7
Frontiers in Immunology
○ based on 140 papers
Top 3%
2.5%
8
Journal of Medical Virology
○ based on 95 papers
Top 4%
2.3%
9
Emerging Infectious Diseases
● based on 84 papers
Top 5%
2.3%
10
The Journal of Infectious Diseases
◐ based on 137 papers
Top 5%
2.3%
11
Nature Communications
○ based on 483 papers
Top 30%
1.6%
12
BMJ Open
● based on 553 papers
Top 40%
1.6%
13
New England Journal of Medicine
● based on 49 papers
Top 2%
1.4%
14
Journal of Infection
○ based on 64 papers
Top 4%
1.4%
15
Scientific Reports
○ based on 701 papers
Top 76%
1.4%
16
Clinical Infectious Diseases
◐ based on 219 papers
Top 15%
1.4%
17
Infectious Diseases and Therapy
○ based on 18 papers
Top 1%
0.8%
18
Vaccine: X
○ based on 16 papers
Top 1%
0.8%
19
Frontiers in Medicine
○ based on 99 papers
Top 17%
0.8%
20
Eurosurveillance
● based on 77 papers
Top 9%
0.7%
21
eClinicalMedicine
○ based on 55 papers
Top 6%
0.7%